Neurology & Neurosurgery Research
Parkinson’s Disease and Zoledronic Acid (TOPAZ) Study
AGE: 60 years or older
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Interventional Treatment
HEALTHY PARTICIPANTS: Yes
HEALTHY PARTICIPANTS: Yes
CONDITION: Parkinson’s Disease, parkinsonsism
Learn More About This Research Study
This is a research study being conducted at University Hospitals. For more information, please contact Steven Gunzler at 216-844-8685 (option 3) or complete the online form below.
Study Purpose
The purpose of the TOPAZ study is to determine whether zoledronic acid, an approved bone strengthening medication for osteoporosis, can prevent fractures and decrease the risk of dying in people with Parkinson’s disease and other parkinsonism. The information learned in this study will help doctors understand whether they should treat their patients with PD with zoledronic acid.
Who Can Participate
Participants 60 years of age and older with Parksinson’s disease or another form of parkinsonism who have not had a hip fracture may be eligible for this study.
Study ID
- STUDY20210436